We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOOK
126
DELISTED
HOOKIPA Pharma
HOOK
| $9.15M | 0.2% |
+68,026
| New | +$8.21M |
|
127
Diodes
DIOD
$4.06B
| $9.12M | 0.2% |
114,271
+81,291
| +246% | +$6.43M |
|
128
Coherent
COHR
$63.3B
| $9.1M | 0.2% |
+133,023
| New | +$10.9M |
|
129
ARS Pharmaceuticals
SPRY
$528M
| $9.02M | 0.2% |
206,683
-8,853
| -4% | -$419K |
|
130
Petco
WOOF
$845M
| $8.98M | 0.2% |
+405,153
| New | +$9.65M |
|
|
KNTE
131
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $8.92M | 0.2% |
286,129
+9,678
| +4% | +$337K |
|
132
Agilent Technologies
A
$39.3B
| $8.89M | 0.2% |
+69,960
| New | +$8.65M |
|
133
Dell
DELL
$302B
| $8.8M | 0.2% |
+197,034
| New | +$8.07M |
|
134
Iovance Biotherapeutics
IOVA
$1.95B
| $8.79M | 0.19% |
277,523
+255,949
| +1,186% | +$10.6M |
|
135
eHealth
EHTH
$45.1M
| $8.75M | 0.19% |
+120,261
| New | +$7.69M |
|
136
Aldeyra Therapeutics
ALDX
$93.5M
| $8.68M | 0.19% |
+730,394
| New | +$8.41M |
|
137
AbCellera Biologics
ABCL
$1.86B
| $8.66M | 0.19% |
254,902
-176,185
| -41% | -$7.02M |
|
|
BPMC
138
DELISTED
Blueprint Medicines
BPMC
| $8.64M | 0.19% |
+88,906
| New | +$8.88M |
|
139
American Well
AMWL
$174M
| $8.48M | 0.19% |
24,401
+14,225
| +140% | +$7.71M |
|
140
Arvinas
ARVN
$581M
| $8.48M | 0.19% |
128,250
+3,037
| +2% | +$232K |
|
141
Praxis Precision Medicines
PRAX
$8.64B
| $8.24M | 0.18% |
16,778
-3,358
| -17% | -$2.39M |
|
142
Relay Therapeutics
RLAY
$4.26B
| $8.24M | 0.18% |
238,440
-54,775
| -19% | -$2.38M |
|
|
SNRHU
143
DELISTED
Senior Connect Acquisition Corp. I Unit
SNRHU
| $8.23M | 0.18% |
822,580
-27,420
| -3% | -$291K |
|
144
Lattice Semiconductor
LSCC
$19.6B
| $8.16M | 0.18% |
+181,170
| New | +$8.04M |
|
145
Shoals Technologies Group
SHLS
$1.55B
| $8.09M | 0.18% |
+232,542
| New | +$8.24M |
|
146
Planet Fitness
PLNT
$4.43B
| $8M | 0.18% |
+103,543
| New | +$8.22M |
|
147
Spotify
SPOT
$98.3B
| $8M | 0.18% |
+29,865
| New | +$9.31M |
|
148
Cencora
COR
$59.6B
| $7.92M | 0.18% |
67,046
+58,030
| +644% | +$6.28M |
|
149
Outset Medical
OM
$96.8M
| $7.86M | 0.17% |
9,635
-6
| -0.1% | -$4.63K |
|
150
Penumbra
PEN
$12.8B
| $7.8M | 0.17% |
+28,811
| New | +$7.44M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.